Navigation Links
Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
Date:1/27/2009

- Vimpat(R) demonstrated greater seizure reduction and improved seizure freedom versus placebo when added to first and second-generation antiepileptic drugs (AEDs)

- Phase III study supports recent U.S. FDA and European Commission approvals of Vimpat(R)

ATLANTA, Jan. 27 /PRNewswire-FirstCall/ -- The new antiepileptic drug Vimpat(R) (lacosamide) demonstrated significantly fewer seizures in adult partial-onset epilepsy patients whose seizures were inadequately controlled despite taking up to three other AEDs, according to a Phase III clinical study published online in Epilepsia.

In the study, seizure reduction was measured by:

Primary Endpoints

  • The change in seizure frequency per 28 days from baseline to the maintenance period.
  • The 50 percent responder rate, defined as the proportion of patients experiencing a 50 percent or greater reduction in partial seizure frequency per 28 days from the baseline to the maintenance period.

Secondary Endpoints

  • Seizure freedom:
    • The number and proportion of patients achieving seizure-free status throughout the maintenance period for patients completing the maintenance period.
    • The proportion of seizure-free days during the maintenance period for patients entering the maintenance period.

Vimpat(R) was recently approved by the U.S. Food and Drug Administration (FDA) for use as an add-on therapy for the treatment of partial-onset seizures in adult patients with epilepsy. Earlier this year, the European Commission approved Vimpat(R) for the adjunctive treatment of partial-onset seizures with or without secondary generalization in adult patients with epilepsy.

"These results are particularly encouraging given the number of peopl
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
2. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
3. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
4. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
5. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
8. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
9. Study Shows Machine Perfusion Significantly Improves Transplant Results
10. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
11. New study indicates smallpox vaccination effective for decades
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2013)... 2013 The topics that will be ... scrum framework, scrum roles, scrum meetings, scrum artifacts, and ... units (8 PDUs) for attending them. , These trainings ... managers, directors. It is also ideal for those who ... outside the software industry or those who want to ...
(Date:6/14/2013)... Case Western Reserve University, in ... Valtronic, has been awarded a $3 million grant ... a neurostimulation technology platform designed to treat multiple ... and muscle paralysis. , The Ohio ... with the technology development and innovation capabilities of ...
(Date:6/14/2013)... Pittsburgh, PA (PRWEB) June 14, 2013 ... reservations for Pittcon 2014, which will be held March ... facility, located in Chicago, Illinois. The cost per booth ... be included in the first round of booth assignments ... July, as floor placements will begin August 2013. , ...
(Date:6/14/2013)... / Boston, MA (PRWEB) June 14, 2013 ... largest independent resource for life scientists to share ... features within the growing 1DegreeBio marketplace. A first ... through hundreds of vendor catalogues, access community-submitted product ... orders, email products to lab managers and now ...
Breaking Biology Technology:Affordable Scrum Trainings in Chicago on July 12th 2013 by Conscires Agile Practices 2Affordable Scrum Trainings in Chicago on July 12th 2013 by Conscires Agile Practices 3Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 2Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 3Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 4Pittcon 2014 Now Accepting Booth Space Reservations 21DegreeBio Inc. Boosts Review-Driven Reagent Marketplace with New e-Commerce Platform 2
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 2011 Asmacure Ltee, a clinical-stage biopharmaceutical ... for the treatment of asthma and other inflammatory diseases, ... chief executive officer.  With a solid foundation established at ... progresses its lead compound, a potential new treatment for ...
... KONG, June 3, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ... plan to release financial results for the fourth quarter and ... 2011, after market close in the US.   ... ET on Monday, June 13, 2011 to discuss its financial ...
Cached Biology Technology:EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2
(Date:6/14/2013)... World War II soldiers, "The White Cliffs of Dover" ... times. To geographers, the white cliffs mark the point ... scientists, the white cliffs are towering structures made of ... alga known as Emiliania huxleyi . "Ehux" is ... Even though the process by which the alga,s "armor" ...
(Date:6/14/2013)... OttawaJune 14, 2013Here,s a good reason to pay ... has published a paper from Ottawa researchers today, ... in the fight against cancer. The technique predicts ... cancer-killing, oncolytic viruses to overcome the natural defences ... infection. , "Oncolytic viruses are special in ...
(Date:6/13/2013)... The World Cultural Council is proud to announce that ... presentations, with its 30th Award Ceremony on Wednesday, 2nd ... and the Programme will be available shortly. , ... criteria for the Science Award of bringing "true benefit ... a scientific leader of several prestigious organizations, with significant ...
Breaking Biology News(10 mins):Chalking up a marine blooming alga: Genome fills a gap in the tree of life 2Chalking up a marine blooming alga: Genome fills a gap in the tree of life 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 4Using math to kill cancer cells 22013 World Cultural Council awards 22013 World Cultural Council awards 3
... major new review of scientific knowledge on kava a ... with calming effects has left unsolved the mystery of ... in the United States, Europe, and other Western cultures sometimes ... Chemical Research in Toxicology . Line Olsen and colleagues ...
... release is available in German and Spanish ... in Chile pose a higher threat to its neighbour, Argentina, ... University of Concepcin in Chile and the Helmholtz Centre for ... In particular, 22 non-native species which occur in Chile on ...
... , This release is available in German ... protects them against diseases. The early detection of pathogens and ... work as a protective shield. However, the pathogens that cause ... suppress the natural cell wall reaction in plants. "One particularly ...
Cached Biology News:Chile is more dangerous for Argentina than vice versa 2Chile is more dangerous for Argentina than vice versa 3TUM researchers discover a new switch in resistance to plant diseases 2
... Do you need to make your strain ... efficiency? Take advantage of Lucigen’s unrivalled expertise ... Competent Cell Service offers: Chemically ... efficiencies Fast turnaround ...
Choriongonadotropin (human, hCG)...
... Sciences provides a comprehensive kinase analysis ... substrate (PKS) peptide microarrays synthesized on ... kinase profiling, quantitative measurement of kinase ... This comprehensive service includes preparation of ...
... Running Buffer was designed to meet the ... todays sequencing labs. As a primary manufacturer ... gel-based sequencing community Sigma has the know ... your buffer needs. Scientists at Sigma have ...
Biology Products: